GO Therapeutics
One Broadway
Cambridge
Massachusetts
02142
United States
Website: http://gotherapeutics.com
Email: info@gotherapeutics.com
About GO Therapeutics
GO Therapeutics is applying the latest advances in glycobiology to create cancer drugs that are more potent and less toxic. GO Therapeutics’ cancer specific antibodies against tumor-specific antigens can be used in a multimodal approach to killing cancer, such as antibody-drug-conjugates, bi-specific T-cell engagers and immune-based cell therapies. The company’s scientific team includes some of the leading scientific researchers and applied biologists in glycoproteomics. GO Therapeutics is based in Cambridge, MA.LEADERSHIP:
Founder and CEO: Constantine Therodoropulos
Founder and CSO: Thayer White
CLINICAL TRIAL:
Please click here for clinical trial information.
3 articles with GO Therapeutics
-
GO Therapeutics, headquartered in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.
-
GO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment
10/2/2018
GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target to develop and commercialize a new glycotargeting bispecific antibody.
-
Salubris Pharma Invests $5 Million in Boston's GO Therapeutics
9/27/2017